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Background: The purpose of this study was to evaluate the initial and long-term results of endovascular treatment (EVT)
in patients with symptomatic high-grade extracranial vertebral artery (VA) origin stenosis.
Methods: From February 2001 to March 2013, 73 consecutive patients (33 men with a mean age of 61.7 6 8.8 years)
underwent EVT for symptomatic high-grade VA stenosis. Preoperative evaluation included Duplex ultrasonography and
arteriography. After successful treatment, all patients were followed up at 1, 3, 6, and 12 months after the procedure and
every 6 months thereafter.
Results: Successful EVT of the VA stenosis was achieved in 68 patients (93.2%). All procedures were performed without
use of cerebral protection. The early complication rate was 5.5%, which included one periprocedural transient ischemic
attack, two hematomas at the puncture site, and one allergic reaction to the contrast agent. No in-hospital deaths
occurred. During follow-up (mean, 44.3 6 31.2 months; range, 2-144 months), the primary patency rates at 1, 3, 5, and
7 years were 98.4%, 87.3%, 87.3%, and 87.3%, respectively. Ultrasound Doppler controls during follow-up detected seven
VA restenoses (10.3%). Univariate analysis failed to identify any variable predictive of long-term patency of successfully
treated VA stenosis.
Conclusions: EVT of symptomatic VA origin stenosis is a safe and effective procedure associated with low risk and good
long-term results, even without use of cerebral protection devices. (J Vasc Surg 2014;60:92-7.)Atherosclerotic vertebral artery (VA) stenosis is the sec-
ond most common supra-aortic branch lesion after internal
carotid artery (ICA) stenosis.1,2 VA stenosis is a potential
cause of posterior circulation ischemia, and about 20% to
25% of ischemic strokes occur in the vertebro basilar terri-
tory.3,4 Approximately 30% of lesions of the VA are located
either extracranially or intracranially; about 20% are at the
basilar artery.5 Another signiﬁcance of the VA is that
branches of both VAs make the anterior spinal artery,
one of the main artery suppliers of the spinal cord. There
are several management options for VA stenosis, including
medical, surgical, and endovascular approaches. The cur-
rent study was undertaken to review our 12-year experi-
ence of angioplasty and angioplasty with stenting of
extracranial VA stenosis to evaluate the safety, short- and
long-term patency, clinical success rates, and predictive
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From February 2001 to March 2013, 73 consecutive
patients (33 men with a mean age of 61.7 6 8.8 years) un-
derwent endovascular treatment (EVT) of symptomatic
high-grade VA stenosis (70%-99%) at the University Car-
diovascular Clinic. Patients with VA occlusion and with
the lesion distal to the V1 segment were not included in
the analysis. Preprocedural evaluation included clinical ex-
amination and duplex ultrasound scanning of the extracra-
nial carotid arteries, subclavian artery (SA), and VA. For
the ultrasonic assessment of our patients, we used the
European Carotid Surgery Trial method6 to deﬁne the de-
gree of VA stenosis. Medical records were reviewed for de-
mographic data, procedural and lesion-speciﬁc factors,
complications, and outcome variables. The neurologic ex-
amination was performed before and after the procedure
by two experienced neurologists who were blinded for
the study results. Neurologic symptoms were vertigo in
36 patients (49.4%), diplopia in 10 (13.7%), recurrent syn-
cope in 9 (12.3%), speech disturbance in 3 (4.1%), head-
ache in 2 (2.8%), and ataxia in 1 (1.4%). Of these, 14
were classiﬁed as a posterior circulation transient ischemic
attack (TIA) by a neurologist (8 cases of diplopia, 2 cases
of vertigo, 3 cases of speech disturbance, and one case of
ataxia). TIA was deﬁned as a brief episode of neurologic
dysfunction caused by a focal disturbance of brain ischemia
without imaging evidence of infarction. The remaining 12
patients (16.3%) had prior stroke in the posterior circula-
tion in the past 6 months (four recurrent strokes), which
classiﬁed them as symptomatic. Because all patients under-
went brain computed tomography (CT) before interven-
tion and ﬁnal diagnosis, the stroke in the anterior
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of the presenting symptoms, such as hypotension and oto-
genic and cardiac disorders, were excluded. The status of
the contralateral VA was graded as follows: mild stenosis
(<50%), 34 patients (46.6%); moderate stenosis (50%-
69%), eight patients (11%); and severe stenosis (70%-
99%), four patients (5.5%). Contralateral VA occlusion
was found in 22 patients (30%), whereas it was absent in
two patients (2.7%), and three patients (4.1%) had an
atretic (<2 mm) contralateral VA.
Diagnosis of the VA stenosis was conﬁrmed by digital
subtraction angiography in nine patients from 2001 to
2005 by quantitative stenosis analysis. After 2005, multi-
slice CT angiography (Lightspeed VCT; GE Healthcare,
Milwaukee, Wisc) was used in 64 patients. Diagnosis of
VA stenosis by multislice CT was made with Advantage
Workstation software AW 4.3. VA anatomy was analyzed
by a volume rendering three-dimensional protocol. Steno-
sis analysis was performed with the curved multiplanar
reconstruction protocol, and the VA lumen was measured
with a digital ruler (1-mm resolution). The degree of ste-
nosis was calculated with the following equation:
stenosis ¼ (1  minimal residual lumen/distal VA
diameter)  100%. In our center, the agreement between
color Doppler ultrasound and digital subtraction angiog-
raphy is 98%; between color Doppler ultrasound and CT
angiography, it is 97%. All patients signed the informed
consent for use of their data for the analysis. The study
was approved by our local ethical committee.
Interventional procedure and administration of
drugs. After the diagnosis of VA stenosis was made, every
patient was seen by the neurologist and the vascular sur-
geon. Best medical therapy was prescribed in all the pa-
tients, except in the patients with posterior circulation
TIAs and patients with simultaneous carotid artery and
VA near-total occlusion, which required immediate treat-
ment. If there was no symptom improvement under best
medical therapy for at least 2 months, the indication for
EVT was made by an interdisciplinary group (vascular
surgeon, neurologist, and interventional radiologist). All
procedures were performed by interventional vascular
specialists in a Siemens AXIOM Artis dFA (Siemens
Medical Solutions, Malvern, Pa) angiography suite. In
every consecutive patient, at least 3 days before the inter-
vention, acetylsalicylic acid (100 mg/d) and either ticlo-
pidine (250 mg twice daily) or clopidogrel (75 mg/d) were
administered. Since 2002, after the intervention, dual an-
tiplatelet therapy was administered to all patients for
12 months, and acetylsalicylic acid (100 mg/d) was
continued. Statins were administered in 61 of 73 patients
(83.6%) on discharge. All procedures were performed un-
der local anesthesia (lidocaine 1%). The procedure was
performed under systemic anticoagulation (heparin in
doses of 100 units/kg) to have the activated clothing time
between 250 and 300 seconds. Selection of the puncture
site was tailored to the individual patient’s anatomy; it was
the common femoral artery in 87% of patients, followed by
the radial artery (8%) and brachial artery (5%). A 6F Judkinsright, VA, or internal mammary artery catheter was used to
engage the SA. A 6F or 7F guiding catheter was advanced to
the stenosis over a 0.035-inch wire. Sometimes we used a
buddy wire positioned in the distal SA to provide additional
stability for the guiding catheter. The lesion was traversed
with a 0.014-inch steerable guidewire, usually BMW Uni-
versal or Whisper (Abbott, Abbott Park, Ill). Depending on
the severity of stenosis, predilation was performed with a
balloon that was undersized compared with the reference
vessel diameter. Selection of balloon size, stent type, and
stent size was left to the discretion of the interventionist.
The stents most often used were low-proﬁle balloon-
expandable coronary stents: Driver (Medtronic, Santa
Clara, Calif), 16 (25.8%); Tsunami (Terumo Corp, Tokyo,
Japan), 14 (22.7%); FlexMaster F1 (Abbott), 13 (21%);
Multilink Vision (Abbott), 6 (9.7); Liberté (Boston Scien-
tiﬁc Corp, Natick, Mass), 4 (6.5%); Integrity (Medtronic,
Minneapolis, Minn), 4 (6.5%); and peripheral Palmaz Blue
stent (Cordis Corp, Warren, NJ), 5 (8%). The proximal
portion of the stent was positioned with one or two cells
protruding into the SA to prevent prolapse of SA plaque into
the VA. The degree of residual stenosis in the stented VA
was measured by quantitative stenosis analysis on a post-
treatment catheter angiogram. In six patients, only balloon
dilation was used when the response to predilation was a
stent-like result without any residual stenosis. All procedures
were performed without use of cerebral protection.
Follow-up and deﬁnitions. During follow-up, pa-
tients were examined by the attending surgeon, and the
duplex ultrasound controls were performed at 1, 3, and
6 months in the ﬁrst year and every 6 months thereafter or
whenever new symptoms appeared. Technical success was
deﬁned as a reduction in stenosis severity to <20% luminal
narrowing with symptom resolution. Clinical success was
deﬁned as technical success related to periprocedural events
from the initiation of the procedure through the ﬁrst
24-hour postoperative period7 and with symptom resolu-
tion beyond 24 hours after the procedure. Clinical failure
was deﬁned as a resumption of clinical symptoms with
recurring stenosis (>50%) at 1 year after the index proce-
dure conﬁrmed by duplex ultrasound or arteriography.
Ischemic cerebrovascular events (strokes, TIA) and wors-
ening of symptoms were assessed.
Statistical analysis. Standard descriptive statistics were
used. Kaplan-Meier curves were constructed to assess
patency as well as to assess survival during the follow-up
period. Cox univariate and multivariate analyses were per-
formed to assess predictors of survival. Patency rates and
mortality were calculated only for patients in whom initial
EVT was successful. Individual differences were considered
to be statistically signiﬁcant for P < .05. SPSS version 17.0
(SPSS Inc, Chicago, Ill) was used for all statistical
calculations.
RESULTS
Initial results. All lesions were located in the ostial
part of the VA (V1). Technical success was achieved in
68 patients (93.2%), whereas the percutaneous approach
Table. Demographic characteristics of enrolled patients,
indication for treatment, and lesion characteristics
Variable n ¼ 73 %
Median age, years 61.7 6 8.8
Male sex 33 45.2
Smoking 52 71.2
HTN 68 93.2
HLP 61 83.6
DM 26 35.6
Family 39 53.4
CAD 33 45.2
ICAD 14 19.2
Prior CEA 35 48
SAD 11 15.1
PAD 21 28.8
Prior TIA 14 19.2
Prior stroke 22 30.1
Mean VA stenosis d 85.7 6 9.2
Lesion side, left 35 47.9
Average lesion length, mm 16.2 6 7.3
CAD, Coronary artery disease; CEA, carotid endarterectomy; DM, diabetes
mellitus; Family, family history of atherosclerotic disease; HLP, hyper-
lipoproteinemia; HTN, hypertension; ICAD, internal carotid artery disease;
PAD, peripheral artery disease; SAD, subclavian artery disease; TIA, tran-
sient ischemic attack; VA, vertebral artery.
Fig 1. Kaplan-Meier curves for the presence of restenosis for the
patients with successful endovascular treatment (EVT). The stan-
dard error is <10% throughout the graph.
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ﬁcation in four and tortuosity in one. Direct stenting was
performed in 50 cases (68.5%) with bare metal stents
(mean stent diameter, 4.376 0.64 mm; mean stent length,
16.57 6 7.6 mm). Two stents were used in ﬁve lesions
(7.3%). In 12 patients (16.4%), balloon angioplasty was
used for predilation for very tight stenosis to allow later
passage of the stent. Six patients (8.2%) were treated with
percutaneous transluminal angioplasty alone. Baseline de-
mographic characteristics of enrolled patients, indication
for treatment, and lesion characteristics are shown in the
Table.
Additional endovascular procedures were performed in
11 patients (15.1%). SA occlusion was found in ﬁve (6.9%),
whereas six patients (8.2%) had SA stenosis. These patients
received EVT (recanalization and stenting) in the same ses-
sion, followed by ostial VA stenting. In nine patients
(12.3%), we performed combined EVT (for VA stenosis)
and open surgical carotid artery procedures because of
high-grade ICA stenosis and contralateral ICA occlusion.
To prevent an ischemic event, we ﬁrst performed VA stent-
ing to enable adequate cerebral perfusion, and carotid end-
arterectomy (CEA) was done in the next step.
No in-hospital deaths occurred. A neurologic compli-
cation, periprocedural TIA, was noted in one patient.
This patient complained of diplopia during balloon dila-
tion. The patient fully recovered after 60 seconds, and
the postprocedural intracranial angiogram and brain CT
scan were unremarkable. No speciﬁc therapy was given.
Other complications included hematoma at the punc-
ture site in two patients (one required surgical treatment)
and one allergic reaction to the contrast material. These
complications were successfully resolved in all cases. After
the initial 30-day periprocedural period, there was no deathor neurologic, vascular access site, or other complication.
None of the symptoms worsened, including in nine pa-
tients (12.4%) with ICA stenosis and contralateral ICA
occlusion.
In patients with EVT failure, the severe artery calciﬁca-
tion was found in the target vessel in all four patients. Be-
sides target vessel calciﬁcation, one patient had severe
calciﬁcation of all the supra-aortic branches and aortic
arch. In these four patients, the lesion was refractory to
balloon inﬂation, and because of the possibility of plaque
rupture or vessel dissection, the intervention was aborted.
The tortuosity in the ﬁfth patient was located directly to
the SA, and the intervention failed because the balloon
could not cross the tortuous lesion. This patient and two
patients with severe artery calciﬁcation were switched to
surgical treatment (one transposition and two bypass graft-
ing procedures). A patient with severe calciﬁcation of the
supra-aortic branches and aortic arch was unsuitable for
the surgical treatment, and the last one refused surgery.
These two patients died during follow-up (after 30 months
and 89 months).
Follow-up data. The median follow-up period was
44.3 6 31.2 months (range, 2-144 months). Four patients
(5.5%) were lost during the follow-up period. Ultrasound
Doppler controls during follow-up detected seven reste-
noses (10.3%). Four secondary endovascular repeated in-
terventions were performed because of symptomatic
moderate restenosis at 6, 14, 24, and 24 months, respec-
tively (median, 17 months), after the index procedure. The
recurrent symptoms were similar to those before inter-
vention (vertigo, three patients; headache, one patient).
Before reintervention, the same examinations as before the
index intervention were performed to exclude other
possible causes.
Another three patients had asymptomatic mild to mod-
erate restenosis and were treated by drug therapy and
controlled every 3 months with ultrasound Doppler exam-
ination. Fig 1 shows Kaplan-Meier curves for the presence
Fig 2. Kaplan-Meier curves depicting mortality for all the patients
with successful endovascular treatment (EVT). The standard error
is <10% throughout the graph.
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patients (9.6%) died during follow-up: 4 patients from car-
diac causes (all had a prior history of ischemic heart dis-
ease), 2 patients from fatal carotid territory stroke of
uncertain cause, and 1 patient as a result of malignant dis-
ease. Fig 2 shows Kaplan-Meier curves for mortality for all
of the patients with successful EVT. After the index proce-
dure, 27 patients (including nine with scheduled CEA) un-
derwent various cardiovascular interventions: 2 patients
underwent carotid angioplasty; 3 patients, SA angioplasty;
4 patients, coronary angioplasty; 4 patients, aortocoronary
bypass grafting; 4 patients, CEA; and 1 patient, aortobife-
moral bypass grafting.
Univariate analysis evaluating the following factors
failed to identify any variable predictive of successful
EVT: age; sex; risk factors for vascular disease; presence
of carotid, subclavian, cardiac, and peripheral artery dis-
eases; length and side of the occlusion; and stent used.
DISCUSSION
In current clinical practice, EVT of a symptomatic
high-grade (>70%) VA stenosis is a reasonable therapeutic
option to improve the vertebrobasilar blood supply.
Numerous previous published studies have shown the re-
sults of EVT of extracranial VA stenosis. However, one
of the limitations of these studies is the relatively short
follow-up.8,9 The current study shows the results of our
12-year experience of angioplasty and angioplasty with
stenting of extracranial VA stenosis. The main ﬁnding of
our study is that patients with symptomatic VA stenosis
have low procedural risk and good long-term results.
Patency rates at 1, 3, 5, and 7 years were 98.4%, 87.3%,
87.3%, and 87.3%, respectively. In addition, during follow-
up (mean, 44.3 6 31.2 months; range, 2-144 months),
seven patients developed restenosis. The univariate analysis
failed to identify any variable predictive factor associated
with restenosis after EVT.Medical treatment is not well established in the litera-
ture. Also, there is a lack of data for medical therapies
related to VA restenosis after EVT. Optimal medical ther-
apy for patients with VA stenosis should include antiplatelet
medication for ﬁrst-line prevention of stroke, risk factor
modiﬁcations, and statin therapy.10 To date, there have
been no randomized trials of the use of different antiplate-
let therapies or anticoagulation vs antiplatelet therapy in
patients with extracranial VA stenosis. Sivenius et al11
found in the European Stroke Prevention Study that a
combination of aspirin and dipyridamole signiﬁcantly
reduced the rate of stroke in the patients with vertebroba-
silar insufﬁciency compared with placebo. In the Carotid
And Vertebral Artery Transluminal Angioplasty Study
(CAVATAS), Coward et al12 compared endovascular and
best medical treatment in patients with symptomatic VA
stenosis. This trial failed to show a beneﬁt of EVT for
VA stenosis, with the limitation of small numbers of pa-
tients included (n ¼ 16). However, the investigators found
that no patient in either group experienced a vertebrobasi-
lar stroke during a mean follow-up period of 4.7 years, but
the initial results were better in the medical treatment
group; two patients (25%) had TIAs at the time of EVT.
There are several surgical techniques for the treatment
of VA stenosis; but in clinical practice, surgical treatment is
technically demanding because of difﬁcult access to the
vessel origin, and it requires experienced surgeons. In addi-
tion, the combined morbidity and mortality rates after sur-
gery range from 10% to 20%, and the risk of cranial
neuropathies (such as Horner syndrome) and nonneuro-
logic complications (lymphocele, wound infection, and
pneumothorax) is high.13-17 Also, long-term results are
not promising; the incidence of vertebrobasilar stroke and
TIA rates in several series during the follow-up period
(mean time, 37 and 86 months) were 9.4% to 11.7%,
and the incidence of restenosis ranged from 19% to
33%.16,18,19 On the other hand, the study of Berguer
et al20 published in 2000 compared surgical results of pa-
tients treated before 1991 (n ¼ 215) and after 1991
(n ¼ 154). Surgical outcome after 1991, supported with
digital arteriography in the operating theater, a trained
anesthesia team, and established uniform management pro-
tocols, showed signiﬁcant improvement. The vascular and
neurologic complication rates and death rates were signiﬁ-
cantly lower in the patients operated on after 1991. How-
ever, it appears that the 5-year primary patency rates were
similar in both groups (80%).
Surgical treatment may be the only viable treatment
option in those patients who fail to respond to medical
therapy and have lesions or anatomy unfavorable to EVT.
In clinical practice, vascular reconstruction by EVT is logi-
cally a reasonable option to improve the vertebrobasilar
blood supply in patients with VA stenosis. The ﬁrst case
of VA origin angioplasty was published in 1981 by Motar-
jeme et al.21 Until the mid-1990s, angioplasty with no
stent implantation was the treatment option for patients
with VA stenosis, with low complication rates and low inci-
dence of restenosis.22
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in 2011 comprised 27 case series and showed a technical
success rate similar to that of our study, with low peripro-
cedural complication, mortality, and morbidity. In
contrast, the restenosis rate in this meta-analysis was
20.8% vs 10.3% in our series.
Another review9 published in 2012 that comprised 690
patients (737 lesions) with extracranial VA stenosis treated
endovascularly showed similarly low technical and clinical
complication rates. In this review, the rate of restenosis
was signiﬁcantly higher than in our series, especially after
implantation of a bare metal stent (mean, 27%; range,
3%-48%), during the follow-up period (mean, 12.8 months;
range, 6-36 months). In the same review, in the drug-
eluting stent (DES) series, the restenosis rate was lower
(mean, 14%; range, 0%-63%) during an average follow-up
period of 5.7 months.
One of the possible explanations for the low restenosis
rate might be SA revascularization. In our group, 17 pa-
tients (25%) had SA treatment: 3 patients had a prior VA
angioplasty, 11 patients had a simultaneous procedure
(SA and VA stenting), and 3 patients received SA stenting
after VA treatment (after 12, 16, and 17 months). Werner
et al23 found that SA stenosis is a signiﬁcant predictor of
VA restenosis. A second potential explanation may be the
extensive and prolonged use of high-dose statins in
83.6% of patients. Another advantage of our study is a
long surveillance period; however, as can be seen from
Kaplan-Meier curves, all restenosis occurred in a period
of almost 2 years after EVT (range, 6-28 months). After
this period, there was no evidence of VA restenosis. The
cited meta-analysis8 and review article,9 which comprised
all high-volume studies of EVT of VA stenosis, showed a
higher restenosis rate, but all were limited with a short
follow-up period (mean, 12.8 months; range, 6-
36 months). These facts lead to the possible important
conclusion that the peak incidence of VA restenosis is dur-
ing 2 to 3 years after EVT.
In recent years, most series24-26 have reported predom-
inantly use of the DES for treatment of VA stenosis. Akins
et al27 suggested that placement of a DES reduces in-stent
restenosis, but it is difﬁcult to draw lessons from this study
because of the small number of patients (n ¼ 12). Howev-
er, DES studies24-26 showed technical and clinical compli-
cation rates similar to those in our study, and the rate of
signiﬁcant restenosis ranged from 7% to 17% during a
follow-up period of 6, 7, and 12 months, respectively.
In the case of a concomitant lesion of the ipsilateral SA
and VA, our practice is to treat both lesions in the same ses-
sion. There are several advantages to this approach: com-
plete revascularization in one session; SA treatment allows
an adequate approach to and technically easier treatment
of the VA stenosis; reduction in the rate of embolization;
and improvement in the left internal mammary artery graft
perfusion in the patients with coronary artery bypass
grafts.28 Also, as reported by Werner et al,23 VA restenosis
occurs signiﬁcantly more often in patients with an ipsilat-
eral SA stenosis.Another important message from this study is that EVT
of VA stenosis allows safe revascularization of the multiple
occlusive lesions of the supra-aortic arteries. In nine pa-
tients (12.3%), EVT of the VA stenosis was performed
before CEA and enabled adequate cerebral perfusion dur-
ing surgical treatment of a single ICA in the next step.
During the procedure, we did not use cerebral protec-
tion in any patients. The role of distal embolic protection
devices in VA stenting is unclear. Mintz et al29 showed
that only low numbers of microemboli signals were
detected during VA stenting. However, the study per-
formed by Qureshi et al30 showed that stenting of the
VA oriﬁce with use of an embolism protection device is
feasible and safe. In addition, during 1-month follow-up,
no stroke or death was observed in 12 patients. On the
other hand, the use of embolic protection devices is difﬁ-
cult in cases with high-grade stenosis and small diameter
of the VA. Wehman et al31 made a similar recommenda-
tion: the use of an embolic protection device for a larger
VA (diameter > 3.5 mm) and in patients who have a favor-
able angle of the VA oriﬁce and for the treatment of ulcer-
ated lesions. Nevertheless, only one patient in our study
had TIA during the intervention.
Limitations of the study. The treatment period was
long, from 2001 to 2013, but all patients are consecutive.
During the study period, the evolution of endovascular
tools contributed to good initial results. Our study showed
a good long-term result and additionally conﬁrmed the
beneﬁt of EVT.
The use of different stents did not allow evaluation of
different stent types with respect to early and long-term re-
sults. The conduct of randomized trials seems to be impos-
sible, so that clinical series, like ours, may contribute to a
better understanding of the value of EVT for VA symptom-
atic stenosis. Also, because of the small number of patients
treated with angioplasty only (n ¼ 6; 8.2%), we did not
perform subgroup analysis (ie, percutaneous transluminal
angioplasty alone vs stent placement). In addition, no
restenosis occurred in these six patients during the
follow-up period.
CONCLUSIONS
EVT of symptomatic VA origin stenosis is a safe and
effective procedure associated with low risk and good
long-term results, even without use of cerebral protection
devices.
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